Although PD-L1 expression in tumor cells guides the use of anti-PD-1/PD-L1 in NSCLC and other cancers, its role as a biomarker is controversial due to its dynamic nature and limited predictive accuracy [43]. The gene discussed is PDCD1; the disease is neoplasm.